Skip to content

Our Company
Our Science
- Overview
- Manufacturing
Our Pipeline
News + Resources
- Press Releases
- Presentations + Publications
Careers
Contact

Our Company
Our Science
- Overview
- Manufacturing
Our Pipeline
News + Resources
- Press Releases
- Presentations
Careers
Contact

Accessibility
Privacy Policy
Transparency in Coverage
Sitemap

Presentations + Publications

Search presentations

Presentation

Potent in vivo CAR T cell generation and durable antitumor activity in preclinical models using VivoVec, a surface-engineered lentiviral vector platform

May 19, 2023

Publication

Preclinical proof of concept for VivoVec, a lentiviral-based platform for in vivo CAR T-cell engineering

Journal for ImmunoTherapy of Cancer

March 16, 2023

Presentation

VivoVec lentiviral vector particles surface-engineered with T cell activating and co-stimulatory ligands enhance in vivo CAR T cell generation and antitumor activity

November 11, 2022

Presentation

In vivo generation of universal CAR T cells that mediate durable anti-tumor immunity through combinatorial targeting with bispecific small molecule adaptors

November 10, 2022

Presentation

VivoVec: A novel lentiviral-based in vivo CAR T cell generation platform with viral particle
surface engineering incorporating T cell activating and co-stimulatory ligands

May 18, 2022

Our Company
Our Science
Manufacturing
Our Pipeline
Careers

Press Releases
Presentations

1150 Eastlake Ave E,
Suite 400
Seattle, WA 98109
info@umoja-biopharma.com

Accessibility
Privacy Policy
Transparency in Coverage
Sitemap

© 2026 Umoja Biopharma. All rights reserved.